GlassScriptPhysician profile
Matthew Churchill
NPI 1235335993
$1,828.38
in general payments reported to CMS, 2019-2025
34 companies · $331 in 2025
The $331 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $565 · 2020: $160 · 2021: $150 · 2022: $40.52 · 2023: $90.36 · 2024: $491 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $912.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $392.61 | 2021-2025 | Ubrelvy |
| Lilly USA, LLC | $183.57 | 2024-2025 | Kisunla, Amyvid |
| Allergan, INC. | $142.43 | 2019-2022 | |
| Pfizer INC. | $88.93 | 2019-2025 | |
| Ucb, INC. | $69.83 | 2019-2024 | Fintepla |
| Supernus Pharmaceuticals, INC. | $69.82 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $65.68 | 2019-2021 | |
| Lundbeck LLC | $64.68 | 2020-2025 | Rexulti, Vyepti |
| Life Molecular Imaging LTD | $60.35 | 2024-2025 | Neuraceq |
| Novartis Pharmaceuticals Corporation | $55.18 | 2019 | |
| Argenx US, INC. | $47.96 | 2024-2025 | Vyvgart Hytrulo |
| Sunovion Pharmaceuticals INC. | $44.67 | 2019 | |
| Genzyme Corporation | $43.86 | 2019 | |
| Biogen, INC. | $43.00 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $38.31 | 2024-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $37.99 | 2019-2020 | |
| Amgen INC. | $34.56 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.50 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $34.03 | 2019-2020 | |
| Emd Serono, INC. | $30.34 | 2019-2020 | |
| Tanabe Pharma America, INC. | $27.51 | 2023 | |
| Neurocrine Biosciences, INC. | $24.00 | 2019 | |
| Amylyx Pharmaceuticals, INC. | $22.51 | 2023 | Relyvrio |
| Scilex Pharmaceuticals INC. | $20.99 | 2019 | |
| Alexion Pharmaceuticals, INC. | $19.50 | 2019 | |
| Adamas Pharmaceuticals, INC. | $17.52 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.27 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $15.98 | 2024 | Rexulti |
| Vertical Pharmaceuticals, LLC | $14.91 | 2019 | |
| Avanir Pharmaceuticals, INC. | $14.89 | 2019 | |
| Amneal Pharmaceuticals LLC | $14.03 | 2025 | Brekiya |
| Eisai INC. | $13.45 | 2019 | |
| Acorda Therapeutics, INC | $13.14 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $11.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Churchill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.